Krystal Biotech (KRYS)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.65 (+0.89%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Krystal Biotech (KRYS)
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Key Insights

Critical company metrics and information

  • Share Price

    $187.62

  • Market Cap

    $5.40 Billion

  • Total Outstanding Shares

    28.76 Million Shares

  • Total Employees

    229

  • Dividend

    No dividend

  • IPO Date

    September 20, 2017

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.krystalbio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$63.34 Million
Net Cash Flow, Continuing$729000.00
Net Cash Flow From Investing Activities, Continuing$-89.82 Million
Exchange Gains/Losses$4000.00
Net Cash Flow From Financing Activities$27.20 Million
Net Cash Flow From Operating Activities, Continuing$63.34 Million
Net Cash Flow$725000.00
Net Cash Flow From Investing Activities$-89.82 Million
Net Cash Flow From Financing Activities, Continuing$27.20 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$52.37 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss$52.37 Million
Costs And Expenses$184.12 Million
Research and Development$51.42 Million
Benefits Costs and Expenses$184.12 Million
Revenues$241.52 Million
Diluted Average Shares$89.20 Million
Basic Earnings Per Share$1.84
Diluted Earnings Per Share$1.78
Income Tax Expense/Benefit$5.03 Million
Operating Expenses$214.06 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Operating Income/Loss$27.45 Million
Income/Loss From Continuing Operations Before Tax$57.40 Million
Other Operating Expenses$153.88 Million
Basic Average Shares$85.95 Million
Net Income/Loss Available To Common Stockholders, Basic$52.37 Million
Net Income/Loss Attributable To Parent$52.37 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Inventory$18.58 Million
Other Non-current Assets$112.56 Million
Liabilities And Equity$982.32 Million
Equity$885.85 Million
Current Assets$713.16 Million
Cash$588.30 Million
Noncurrent Assets$269.15 Million
Noncurrent Liabilities$6.95 Million
Liabilities$96.47 Million
Other Current Assets$106.28 Million
Fixed Assets$156.59 Million
Accounts Payable$5.58 Million
Assets$982.32 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$83.95 Million
Equity Attributable To Parent$885.85 Million
Current Liabilities$89.53 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

â“’ 2024 Financhle. All Rights Reserved.